These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15350897)

  • 1. CDKs: taking on a role as mediators of dopaminergic loss in Parkinson's disease.
    Smith PD; O'Hare MJ; Park DS
    Trends Mol Med; 2004 Sep; 10(9):445-51. PubMed ID: 15350897
    [No Abstract]   [Full Text] [Related]  

  • 2. Time sequences of dopaminergic cell death in Parkinson's disease: indications for neuroprotective studies.
    Gerlach M; Riederer PF
    Adv Neurol; 1999; 80():219-25. PubMed ID: 10410725
    [No Abstract]   [Full Text] [Related]  

  • 3. Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine.
    Rodriguez-Blanco J; Martín V; Herrera F; García-Santos G; Antolín I; Rodriguez C
    J Neurochem; 2008 Oct; 107(1):127-40. PubMed ID: 18665912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of dopamine and Zn2+ on the induction of PC12 cell death and dopamine depletion in the striatum: possible implication in the pathogenesis of Parkinson's disease.
    Lo HS; Chiang HC; Lin AM; Chiang HY; Chu YC; Kao LS
    Neurobiol Dis; 2004 Oct; 17(1):54-61. PubMed ID: 15350965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal dopaminergic neurons are lost with Parkinson's disease progression.
    Porritt MJ; Kingsbury AE; Hughes AJ; Howells DW
    Mov Disord; 2006 Dec; 21(12):2208-11. PubMed ID: 17029264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic neurons reduced to silence by oxidative stress: an early step in the death cascade in Parkinson's disease?
    Michel PP; Ruberg M; Hirsch E
    Sci STKE; 2006 Apr; 2006(332):pe19. PubMed ID: 16639033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease.
    Murrell W; Wetzig A; Donnellan M; Féron F; Burne T; Meedeniya A; Kesby J; Bianco J; Perry C; Silburn P; Mackay-Sim A
    Stem Cells; 2008 Aug; 26(8):2183-92. PubMed ID: 18535154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease.
    Nyholm D
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S13-7. PubMed ID: 17707679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D3 receptor agonists for protection and repair in Parkinson's disease.
    Joyce JN; Millan MJ
    Curr Opin Pharmacol; 2007 Feb; 7(1):100-5. PubMed ID: 17174156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are dopaminergic neurons selectively vulnerable to Parkinson's disease?
    Agid Y; Ruberg M; Javoy-Agid F; Hirsch E; Raisman-Vozari R; Vyas S; Faucheux B; Michel P; Kastner A; Blanchard V
    Adv Neurol; 1993; 60():148-64. PubMed ID: 8420132
    [No Abstract]   [Full Text] [Related]  

  • 14. Protective effect of bromocriptine against BH4-induced Cath.a cell death involving up-regulation of antioxidant enzymes.
    Lim JH; Kim SS; Boo DH; No H; Kang BY; Kim EM; Hwang O; Choi HJ
    Neurosci Lett; 2009 Feb; 451(3):185-9. PubMed ID: 19146917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways.
    Lee DY; Oh YJ; Jin BK
    Glia; 2005 Aug; 51(2):98-110. PubMed ID: 15789435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurochemical correlates of parkinsonism. Role of dopaminergic lesions.
    Hirsch EC; Herrero MT
    Adv Neurol; 1997; 74():119-26. PubMed ID: 9348407
    [No Abstract]   [Full Text] [Related]  

  • 17. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease.
    Jankovic J; Chen S; Le WD
    Prog Neurobiol; 2005; 77(1-2):128-38. PubMed ID: 16243425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dopamine dysregulation syndrome in Parkinson's disease].
    Borg M; Bayreuther C
    Rev Neurol (Paris); 2008 Apr; 164(4):310-21. PubMed ID: 18439923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous regeneration in Parkinson's disease: do we need orthotopic dopaminergic neurogenesis?
    Hermann A; Storch A
    Stem Cells; 2008 Nov; 26(11):2749-52. PubMed ID: 18719222
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.